Value of glucose transport protein 1 expression in detecting lymph node metastasis in patients with colorectal cancer

Table 4 The correlation between hexokinase-II expression and clinicopathologic parameters

	Hexokinase-II (center)		P value	Hexokinase-II (periphery)		P value
	(-) (n = 94)	(+) (n = 70)		(-) (n = 114)	(+) (n = 48)
Age (yr ± SD)	65.1 ± 12.3	63.5 ± 11.6	0.403	64.3 ± 12.3	64.8 ± 11.5	0.806
Sex
Male	61	41	0.409	73	27	0.352
Female	33	29		41	21
Tumor size (mean ± SD)	5.1 ± 1.8	5.1 ± 2.2	0.976	5.1 ± 2.0	5.1 ± 1.9	0.977
T stage
T1, 2	15	7	0.268	16	5	0.531
T3, 4	79	63		98	43
N stage
N0	54	42	0.743	68	28	0.876
N1-2	40	28		46	20
AJCC stage
I, II	53	41	0.779	67	27	0.766
III, IV	41	29		47	21
Lymphatic invasion
Negative	77	61	0.365	97	40	0.778
Positive	17	9		17	8
Perineural invasion
Negative	75	60	0.325	95	38	0.528
Positive	19	10		19	10
Blood glucose level (mean ± SD)	105.2 ± 22.8	116.8 ± 35.1	0.017	110.2 ± 32.0	113.9 ± 31.3	0.493
SUVmax of primary tumor (mean ± SD)	14.0 ± 7.1	14.2 ± 7.7	0.874	14.3 ± 7.2	13.9 ± 7.7	0.786
SUVmax of lymph node (mean ± SD)	1.6 ± 2.8	1.8 ± 3.2	0.712	1.5 ± 2.6	2.0 ± 3.7	0.450

SD: Standard deviation; AJCC: American Joint Committee on Cancer; SUV: Standardized uptake value.